Last C$0.04 CAD
Change Today +0.005 / 16.67%
Volume 152.0K
MBI On Other Exchanges
Symbol
Exchange
Venture
Berlin
OTC US
As of 2:14 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

med biogene inc (MBI) Snapshot

Open
C$0.04
Previous Close
C$0.03
Day High
C$0.04
Day Low
C$0.04
52 Week High
12/27/13 - C$0.13
52 Week Low
11/7/14 - C$0.03
Market Cap
2.9M
Average Volume 10 Days
45.9K
EPS TTM
--
Shares Outstanding
83.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MED BIOGENE INC (MBI)

Related News

No related news articles were found.

med biogene inc (MBI) Related Businessweek News

No Related Businessweek News Found

med biogene inc (MBI) Details

Med BioGene Inc., a life science company, focuses on managing the license and rights to the genomic-based clinical laboratory diagnostic tests. Its products include the GeneFx Lung, a gene expression-based test for early-stage non-small-cell lung cancer that analyzes the molecular profile of a patient’s tumor to provide information to assist in tailoring treatment for that specific patient. The company has a collaboration agreement with the University Health Network. Med BioGene Inc. was founded in 2002 and is headquartered in Vancouver, Canada.

Founded in 2002

med biogene inc (MBI) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

med biogene inc (MBI) Key Developments

Med Biogene Inc. Announces Board and Management Changes

Med Biogene Inc. announced that, at its Annual and Special General Meeting held on September 5, 2014, elected Dr. Iain Weir-Jones, Toby Weir-Jones, David Diebolt and Dr. Terence W. Friedlander, M.D as the Directors of the company. These persons replace all of the incumbent directors of the company. The newly appointed board of directors has appointed Dr. Iain Weir-Jones as Chief Executive Officer and Chairman and Ibrahim Ghobrial as Chief Financial Officer.

Med BioGene Inc. Announces Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Med BioGene Inc. announced earnings results for the second quarter and six months ended June 30, 2014. For the quarter, loss was $57,060 against $139,171 for the same period a year ago. For the six months, loss was $129,881 against $217,585 for the same period a year ago. Cash used in operating activities was $97,967 for the period ended June 30, 2014 compared to cash used in operating activities of $182,779 for the period ended June 30, 2013.

Med BioGene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2014

Med BioGene Inc. reported earnings results for the first quarter ended March 31, 2014. During the three months ended March 31, 2014, net loss was $72,821 against $78,414 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MBI:CN C$0.04 CAD +0.005

MBI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MBI.
View Industry Companies
 

Industry Analysis

MBI

Industry Average

Valuation MBI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 22.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MED BIOGENE INC, please visit www.medbiogene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.